Download this short summary slideset from a live Webinar to review the rationale for PARP inhibitor combination therapy in prostate cancer and current clinical data in metastatic castration-resistant prostate cancer
Download these slides from a live Webinar for the latest evidence on PARP inhibitor monotherapy and factors that impact response to PARP inhibition in metastatic castration-resistant prostate cancer.
Download these slides from a live Webinar to learn about the rationale underlying PARP inhibitor combination therapeutic strategies in metastatic castration-resistant prostate cancer.
Download these slides from a live Webinar to review the most recent clinical data on PARP inhibitors in combination with other agents in metastatic castration-resistant prostate cancer.
Learn about the underlying rationale for PARP combination approaches in prostate cancer and discover the many ongoing clinical trials of PARP inhibitors combined with AR-directed therapy, immunotherapy, or other targeted agents.
In this commentary, gain insights on the rationale for PARP inhibitor combinations in prostate cancer and the latest corresponding evidence available.
In this podcast episode, listen to Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, as they answer questions on the use of PARP inhibitors and PARP inhibitor combinations for patients with prostate cancer.
Download this short summary of key takeaways from a podcast on combination approaches to expand the benefit of PARP inhibitors in prostate cancer.